Defensin (HBD-3) vs LL-37 — Peptide Comparison

Defensin (HBD-3) vs LL-37 — Peptide Comparison Defensin (HBD-3) vs LL-37 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Defensin (HBD-3) 1–50 μg/mL (research) LL-37 0.5–1.6 mg/mL (topical) Frequency As needed Once daily Administration Topical application (research/wound care) Topical application (wound healing) Cycle Length Ongoing/indefinite 12+ weeks Onset Speed Rapid (hours to days) Moderate (1-2 weeks) Evidence Level Moderate human trials (Phase 1-2) Efficacy Fighting Drug-Resistant Bacteria Wound Healing Immune System Support Fighting Infections Immune Boost Technical Data Molecular Formula Approximately C220H340N64O62S6 (45-amino acid peptide with 3 disulfide bonds) Molecular Weight ~5,155 Da (mature peptide) Half-Life Short systemic half-life (minutes) typical of cationic peptides; disulfide-bonded form provides protease resistance at local tissue sites; linear form shows adequate stability for topical applications Bioavailability Topical application achieves high local concentrations; maintains activity in physiological salt environments (unique); linear form retains activity enabling simplified formulation; not intended for oral or systemic delivery CAS Number Not assigned (endogenous human peptide; research-grade available from peptide suppliers) C205H340N60O53 4,493.26 Da Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery 154947-66-7 Protocols standard 200 µg/mL applied to the wound, about 4 µg per dose (20 µL) Every 2 days in the study Until wound healed (study setting) HBD-3 is a research-only peptide with no human dosing protocol. This amount comes from a preclinical infected-diabetic-wound study where it was applied to the wound surface and sped up healing while lowering bacteria [6]. Human use has not been established. starting 0.5 mg/mL gel Twice weekly 4 weeks Lowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4]. 1.6 mg/mL gel Mid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4]. Applications Research into anti-MRSA therapeutics and alternatives to vancomycin for resistant infections Defensin (HBD-3) is particularly well-suited for individuals focused on research into anti-mrsa therapeutics and alternatives to vancomycin for resistant infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Development of antimicrobial wound dressings and medical device coatings Defensin (HBD-3) is particularly well-suited for individuals focused on development of antimicrobial wound dressings and medical device coatings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Anti-biofilm strategies for chronic wound infections and implant-associated infections Defensin (HBD-3) is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and implant-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Applications requiring antimicrobial activity in physiological or high-salt environments Defensin (HBD-3) is particularly well-suited for individuals focused on applications requiring antimicrobial activity in physiological or high-salt environments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas) LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Anti-biofilm strategies for chronic wound infections and medical device-associated infections LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Boosting innate immune defense in immunocompromised or aging individuals LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Safety Profile Common Local site irritation Transient inflammatory response Mild wound bed changes Uncommon Localized allergic reaction Mild cytotoxicity at high concentrations Serious No serious adverse effects documented at therapeutic concentrations Transient stinging or burning Mild perilesional erythema Increased wound exudate Allergic contact reaction Hemolytic activity at systemic concentrations Research Status FDA Status Research compound Safety Overview Defensin HBD-3 is not FDA-approved and has no completed human clinical trials, existing only in research contexts with in vitro and animal study data. Animal toxicology studies demonstrate no major systemic toxicity at doses exceeding therapeutic levels, but human immunological responses to exogenously administered defensin peptides have not been characterized. Risks include potential immune activation, cross-reactivity with self-antigens (due to HBD-3 expression in healthy epithelial cells), development of anti-peptide antibodies, and possible tolerance development with repeated dosing. Bacterial and fungal resistance to defensin-based therapy is theoretically possible. No human pharmacokinetics, dose-ranging studies, Phase 1 safety assessments, or clinical efficacy data exist. Contraindications xKnown hypersensitivity to defensin peptides or formulation components xPregnancy and breastfeeding — insufficient safety data for exogenous defensin administration xActive autoimmune conditions — potential for immune activation through monocyte/macrophage recruitment xSevere hepatic or renal impairment — peptide clearance may be altered for any systemic exposure LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications. xKnown hypersensitivity to cathelicidin peptides or formulation components xActive hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity xPregnancy and breastfeeding — insufficient reproductive safety data from clinical trials xSevere renal impairment — peptide clearance may be altered Decision Guide Choose Defensin (HBD-3) if... Research into anti-MRSA therapeutics and alternatives to vancomycin for resistant infections Development of antimicrobial wound dressings and medical device coatings Anti-biofilm strategies for chronic wound infections and implant-associated infections Applications requiring antimicrobial activity in physiological or high-salt environments Choose LL-37 if... Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas) Anti-biofilm strategies for chronic wound infections and medical device-associated infections Boosting innate immune defense in immunocompromised or aging individuals